Min-Cheng Su1, Chun-Ting Chen1, Fang-I Huang2, Yu-Ling Chen2, Yung-Ming Jeng3, Chiao-Ying Lin4. 1. Department of Pathology, Min-Sheng General Hospital, Taoyuan, Taiwan. 2. Graduate Institute of Pathology, National Taiwan University, Taipei, Taiwan. 3. Graduate Institute of Pathology, National Taiwan University, Taipei, Taiwan; Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan. Electronic address: chengym@ntu.edu.tw. 4. Department of Dentistry, Taipei Medical University, Taipei, Taiwan. Electronic address: dr.cylin@msa.hinet.net.
Abstract
BACKGROUND/ PURPOSE: Lymphoid-enhancing factor 1 (LEF1) is a transcription factor mediating Wnt/β-catenin signaling. In this study, we analyzed the clinicopathologic significance of LEF1 expression in oral squamous cell carcinoma (OSCC). METHODS: Expression levels of LEF1 in 135 cases of OSCC were determined by immunohistochemistry. The results were correlated with clinicopathologic parameters and patient outcome. RESULTS: LEF1 was only occasionally detected in basal and parabasal cells of nontumorous squamous epithelium. Overexpression of LEF1 was observed in 33 of 135 OSCCs (24%). LEF1 was more frequently expressed in moderately to poorly differentiated cancer (p = 0.0035) and was associated with lymphovascular invasion (p = 0.0252). Overexpression of LEF1 was significantly associated with poor prognosis (p = 0.0176, hazard ratio = 1.96, 95% CI = 1.02-3.75). Multivariate analysis revealed LEF1expression and margin status to be the significant independent predictors for overall survival. CONCLUSION: Our study suggests LEF1 expression in OSCC may play an important role in tumor progression and can be served as a predictor of poor prognosis for patients with OSCC.
BACKGROUND/ PURPOSE:Lymphoid-enhancing factor 1 (LEF1) is a transcription factor mediating Wnt/β-catenin signaling. In this study, we analyzed the clinicopathologic significance of LEF1 expression in oral squamous cell carcinoma (OSCC). METHODS: Expression levels of LEF1 in 135 cases of OSCC were determined by immunohistochemistry. The results were correlated with clinicopathologic parameters and patient outcome. RESULTS:LEF1 was only occasionally detected in basal and parabasal cells of nontumorous squamous epithelium. Overexpression of LEF1 was observed in 33 of 135 OSCCs (24%). LEF1 was more frequently expressed in moderately to poorly differentiated cancer (p = 0.0035) and was associated with lymphovascular invasion (p = 0.0252). Overexpression of LEF1 was significantly associated with poor prognosis (p = 0.0176, hazard ratio = 1.96, 95% CI = 1.02-3.75). Multivariate analysis revealed LEF1expression and margin status to be the significant independent predictors for overall survival. CONCLUSION: Our study suggests LEF1 expression in OSCC may play an important role in tumor progression and can be served as a predictor of poor prognosis for patients with OSCC.
Authors: Sarita Joshi; Paula M De Angelis; Manuela Zucknick; Aasa R Schjølberg; Solveig Norheim Andersen; Ole Petter F Clausen Journal: Cancer Rep (Hoboken) Date: 2019-11-11
Authors: Maximilian Krüger; Julianna Amort; Petra Wilgenbus; Johanna P Helmstädter; Irina Grechowa; Julia Ebert; Stefan Tenzer; Maximilian Moergel; Ines Witte; Sven Horke Journal: Oncotarget Date: 2016-08-09